Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (162)
  2. Journal Article (109)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Correspondence (2)
  7. Conference Paper (1)
Groups
  1. Department of Medicine (292)
  2. Solid Tumor Oncology Division (292)
  3. Thoracic Oncology (292)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (105)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (21)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (63)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (86)
  2. American Society of Clinical Oncology (85)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (292)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lung cancer and cardiovascular disease: Common pathophysiology and treatment-emergent toxicity
    Review

    El-Rayes, M.; Nardi Agmon, I.; Yu, C.; Osataphan, N.; Yu, H. A.; Hope, A.; Sacher, A.; Yu, A. F.; Abdel-Qadir, H.; Thavendiranathan, P.
    JACC: CardioOncology (2025)

    Fulltext@MSK | Save
  • Outcomes after radiation for oligoprogressive disease sites in patients with EGFR-mutant lung cancer treated with osimertinib
    Journal Article

    Chen, M. F.; Jeng, M. Y.; Ma, J.; Agrawal, P.; Dunne, E.; Boe, L. A.; Kris, M. G.; Huang, J.; Veeraraghavan, H.; Gomez, D.; more...
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD
    Meeting Abstract

    Le, X.; Hendriks, L.; Morabito, A.; Bonanno, L.; Okamoto, I.; Goldman, J. W.; Yu, H. A.; Brustugun, O. T.; Halvorsen, T. O.; Kim, Y. J.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Phase I study of patritumab deruxtecan (HER3-DXd) in patients (pts) with advanced KRAS G12C non-small cell lung cancer (NSCLC): Study U102 cohort 5
    Meeting Abstract

    Paz-Ares, L.; Steuer, C.; Ruiter, G.; Nishio, M.; Murakami, H.; Kim, D. W.; Felip, E.; Baik, C. S.; Lin, C. C.; Massarelli, E.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib
    Meeting Abstract

    Nadal, E.; Cheema, P. K.; Wu, Y. L.; Ahn, M. J.; Tanizaki, J.; Gharagoozloo, S.; Nizialek, E.; Shi, X.; van der Gronde, T.; Yu, H. A.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Things you should know about managing ALK plus metastatic NSCLC
    Editorial

    Kris, M. G.; Gainor, J.; Preeshagul, I.; Yu, H. A.
    Oncology (Norwalk) (2025)

    Fulltext@MSK | Save
  • Emerging importance of HER3 in tumorigenesis and cancer therapy
    Review

    Garrett, J. T.; Tendler, S.; Feroz, W.; Kilroy, M. K.; Yu, H.
    Nature Reviews Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A podcast discussion on the intracranial efficacy of antibody–Drug conjugates in patients with EGFR-mutated NSCLC with brain metastases
    Editorial

    Johnson, M. L.; Lin, J. J.; Boire, A.; Khandekar, M. J.; Yu, H. A.
    Oncology and Therapy (2025)

    Fulltext@MSK | Save
  • REZILIENT3: Randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC
    Journal Article

    Heymach, J. V.; Yu, H. A.; Besse, B.; Cheng, Y.; Tan, D. S. W.; Wei, L.; Wacheck, V.; Nishio, M.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Consolidation ALK tyrosine kinase inhibitors versus durvalumab or observation after chemoradiation in unresectable stage III ALK-positive NSCLC
    Journal Article

    Nassar, A. H.; Jayakrishnan, R.; Feng, J.; Shepherd, F.; Adib, E.; Cheung, J. M.; Lin, J. J.; Liu, Y.; Lin, S. H.; Parikh, K.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save